Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNP023 versus rituximab in primary membranous nephropathy
NL-OMON52636Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in idiopathic membranous glomerulonephritis (IMG) comparing LNP023 with rituximab (2 arms). Started Oct 2021; status: active, not recruiting.
02
Drugs
Iptacopanrituximab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on NL-OMON52636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52636.